Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00496730
Status:
COMPLETED
Last Update Posted:
2024-05-16
First Post:
2007-07-02
Brief Title:
A Multicenter Randomized Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin 1020 vs Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea 0653A-129COMPLETED
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A Multicenter Randomized Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin 1020 vs Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prevalence of metabolic syndrome in korea is increasing There is no clinical trial targeting on such increasing populations like metabolic syndrome patients with Vytorin in korea Therefore this trial will help evaluate the lipid lowering effect of Vytorin in asian population with metabolic syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007_017 | None | None | None |
| MK0653A-129 | None | None | None |